C-5FX4Fate Therapeutics
iPSC platform, cell programming, cellular immunotherapy
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-5FX4
C-5FX4C-5FX4iPSC platform, cell programming, cellular immunotherapy
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the proportion of participants who achieve complete renal response (CRR) at Week 26.
This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 in combination with trastuzumab or cetuximab; each objective will be assessed with or without paclitaxel chemotherapy.
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate-to-severe active systemic lupus erythematosus (SLE) with or without nephritis, antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.
This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced solid tumors. The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT825 in indication-specific cohorts.
This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy.
This is a Phase I study of FT596 in combination with two different schedules (standard or alternate) of R-CHOP in subjects with B-cell lymphoma who are previously untreated or have received no more than one prior line of treatment. The study will consist of a dose-escalation stage followed by a dose-expansion stage.
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate Therapeutics study and received genetically changed NK cells will take part in this long-term follow-up study. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years starting from the last administration of Fate Therapeutics genetically modified NK cell product, subjects will be assessed for long-term safety and survival through questionnaires and blood tests.
This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The study includes three stages: dose escalation, safety confirmation, and dose expansion.
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study. The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in participants with advanced solid tumors.
This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows: * Regimen A: FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies. * Regimen B: FATE-NK100 in combination with trastuzumab in subjects with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, HER2+ advanced gastric cancer or other advanced HER2+ solid tumors. * Regimen C: FATE-NK100 in combination with cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC), or other epidermal growth factor receptor 1 positive (EGFR1+) advanced solid tumors.
This study is a Phase 1, non-randomized, open-label/Phase 2 randomized, blinded study of ProTmune (ex vivo programmed mobilized peripheral blood cells) versus non-programmed mobilized peripheral blood cells for allogeneic hematopoietic cell transplantation (HCT) in adult subjects aged 18 years and older with hematologic malignancies. A total of 88 study subjects were treated in the trial at approximately 15 centers in the US.
The purpose of this study is to describe the safety profile of ProHema-CB as part of a single cord blood unit transplant after a myeloablative conditioning regimen in pediatric patients with inherited metabolic disorders. The safety profile will primarily be assessed by neutrophil engraftment.
This is an open-label, safety study of a single ProHema-CB product administered following myeloablative conditioning regimen in pediatric subjects with hematologic malignancies.
This study is an open-label randomized, prospectively and historically controlled trial of the safety and efficacy of a single ProHema-CB unit used as part of a double CB transplant following myeloablative or reduced intensity conditioning for subjects age 15-65 years with hematologic malignancies. A maximum of 60 eligible subjects will be enrolled and treated in the trial at approximately 10 centers within the U.S.
This trial is a prospective, open-label, single-arm trial of the safety of a single FT1050-treated CB unit for hematopoietic reconstitution after a reduced-intensity conditioning regimen for hematologic malignancies. A maximum of 40 eligible adult subjects will be enrolled and treated in the trial at approximately 2-4 centers within the U.S.
The purpose of this research study is to determine the safety and efficacy of a reduced intensity conditioning regimen during a double umbilical cord blood unit transplant with one of the cord blood units modulated with ProHema.
Contact - Fate Therapeutics Fate Therapeutics --> Primary Menu --> Skip to content About Us Overview Leadership Corporate Responsibility Pipeline Overview Product Candidates FT819 FT825 FT836 FT839 FT522 Early/Expanded Access Policy Science Our Cells of Interest iPSC Platform Manufacturing Publications & Presentations Patients Our Commitment Our Therapy Autoimmune Disease Cancer Clinical Trials Collaborations Careers and Culture The Fate Way Join Our Team Investors About Fate Press Releases Events & Presentations Financials & Filings SEC Filings Annual Reports and Proxies Corpor
Fate Therapeutics, Inc. – CIRM Skip to content Grants Management System CIRM Hub Portal Contact Search About Our Mission Our Impact Our Governing Board Strategic Goals Our Team Annual Reports For Researchers Funding Opportunities Information for Applicants Researcher Resources Our Review Process Our Programs Grants Dashboard Research and Development Education and Training Patient Access Patient Resources Stem Cell and Genetic Research From Bench to Bedside Community Outreach Clinical Trials Community Stories News and Events Press Releases Public Meetings Blog Webinars and Workshops About … Webinars and Workshops Fate Therapeutics, Inc. Return to Grants Total Awards: 3 Award Value: $15,934,448 Institution type: For profit Short Name: Fate Therapeutics Awards to the Institution Program Type Investigator Grant Title Award Value Therapeutic Translational Research Projects Martin Hosking Development of an off-the-shelf iPSC derived CAR T cell therapy for the treatment of solid tumors $4,000,000 Clinical Trial Stage Projects Dr. Vaneet Sandhu A Phase 1 Study of FT819
Fate Therapeutics Announces Leadership Transition as Bob Valamehr, Ph.D. MBA, to Succeed Scott Wolchko as President and CEO Effective January 1, 2025 | Quiver Quantitative --> Skip to Main Content MEMORIAL DAY API SALE 50% off your first year of Quiver API ... Use Promo Code: MEM50 Quiver API --> × Get a Free Trial on Quiver Premium Today! Upgrade Now Upgrade × Get Email Alerts On FATE Stock Enter your email to receive free breaking news alerts and insights related to FATE. Sign Up Now (Free) Home Datasets Most Popular Politician Search Congress Trading 2026 Midterm Elections Donal … actions, check out Quiver Quantitative's insider trading dashboard. $FATE Hedge Fund Activity We have seen 59 institutional investors add shares of $FATE stock to their portfolio, and 113 decrease their positions in their most recent quarter. Here are some of the largest recent moves: BOXER CAPITAL, LLC removed 3,255,000 shares (-39.6%) from their portfolio in Q3 2024 SUVRETTA CAPITAL MANAGEMENT, LLC removed 2,562,852 shares (-100.0%) from their portfolio in Q2 2024 HOLOCENE
Fate Therapeutics shares ASCO clinical data for FT836 | Fate Therapeutics Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, … forum for advancing cancer care—where groundbreaking research meets real-world application, and collaboration drives meaningful progress for patients. It’s inspiring to be part of a community so deeply committed to transforming outcomes across the oncology landscape. Labcorp , we are proud to support innovation across the continuum—from early development through clinical trials and into clinical practice—helping to accelerate insights that matter most for patients. Looking f
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
Who owns Fate Therapeutics? Top stakeholders of FATE according to 13F filings - stockzoa stockzoa Fund Directory 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X-Z Upgrade to Premium Login Javascript is disabled or is not supported by your browser. Please upgrade your browser or enable Javascript to navigate the interface properly. Who owns Fate Therapeutics? Add alert for FATE Ticker: FATE CUSIP Number: 31189p102 Tip: Access positions for across all investors Analyze quarterly positions in Fate Therapeutics with up to 7 years of data, all consolidated into one spreadsheet Download as csv D … s of Fate Therapeutics stock Who bought or sold Fate Therapeutics this quarter? Fund or Company Name Shares Held Valued At Change in Shares As Of Actions Historical FATE THERAPEUTICS INC position of Redmile Group Source: stockzoa.com " data-trend_url="/ticker/fate/trend/redmile-group-llc/"> Redmile Group 13M $15M 0% Mar 2026 Add alert View chart Historical FATE THERAPEUTICS INC position of BlackRock Source: stockzoa.com " data-trend_url="/ticker/fat … View chart Historical FATE THERAPEUTICS INC position of Dimensional Fund Advisors Source: stockzoa.com " data-trend_url="/ticker/fate/trend/dimensional-fund-advisors-2/"> Dimensional Fund Advisors 884k $1.1M -44% Mar 2026 Add alert View chart Historical FATE THERAPEUTICS INC position of Irenic Capital Management Source: stockzoa.com " data-trend_url="/ticker/fate/trend/irenic-capital-management-lp/"> Irenic Capital Management 878k $1.1M … lert View chart Historical FATE THERAPEUTICS INC position of Privium Fund Management … Source: stockzoa.com " data-trend_url="/ticker/fate/trend/privium-fund-management-bv/"> Privium Fund Management B.V. 414k $497k 12% Mar 2026 Add alert View chart Historical FATE THERAPEUTICS INC position of Susquehanna International Source: stockzoa.com " data-trend_url="/ticker/fate/trend/susquehanna-international/"> Susquehanna International 386k $379 … ckzoa.com " data-trend_url="/ticker/fate/trend/new-york-state-common-retirement-fund/"> New York State Common Retirement Fund 28k $34k 0% Mar 2026 Add alert View chart Historical FATE THERAPEUTICS INC position of Fpc Investment Advisory Source: stockzoa.com " data-trend_url="/ticker/fate/trend/fpc-investment-advisory-in
Gsa Capital Partners Llp – FATE – Fate Therapeutics, Inc. 13F Holdings History GSA CAPITAL PARTNERS LLP 13F Holdings History for Fate Therapeutics, Inc. Symbol FATE CUSIP 31189P102 Investment type Equity Class COM Manager CIK 0001362033 Shares, Excluding Options Value, Excluding Options Holdings date Value ($000) % of Holdings Shares Option Type Filing date All 13F Holders All Managers A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 Latest Filings Privacy Policy
Investors Alley | Page 199 of 207 | Bringing the market closer to you tag on every page of your site.--> Follow us facebook twitter Sunday, June 14, 2026 Menu Home Contact Premium Editors Login Home Contact Premium Editors Login Enphase Energy (ENPH) Earnings Report Show 105% Q1 Revenue Increase Over Year Ago Period May 28, 2020 by Ian Cooper Enphase Energy (ENPH) has been incredibly explosive. Since hitting a low of $21.49 in March 2020, ENPH has rallied to $58.44. Not only did it report impressive earnings, but it also just announced a collaboration with the University of Washington for a 10 … hellip;] Continue Reading → Fate Therapeutics (FATE) Cleared By FDA of IND Application for FT538 May 26, 2020 by Ian Cooper Since April 2020, FATE stock rocketed from a low of $19.92 to $35.23, as it moves progresses with cellular immunotherapies for cancer and immune disorders. Just days ago, FATE announced the U.S. FDA cleared its investigational new drug (IND) application for FT538, the first CRISPR-edited iPSC-derived cell therapy. FT538 is an off the shelf natural [ … ally altered by two trends. The first is the shift from single stock and mutual fund investing into exchange-traded products (primarily ETFs). The second is the emergence of volatility as an asset class. First off, ETFs opened the door for the average investor to trade […] Continue Reading → The World’s First Trillionaire? May 21, 2020 by Eddy Elfenbein Jeff Bezos could become the founding member of the “Four Comma Club” Recently, one of my favorite financial writ … e Magnifi’s Form ADV for additional information about fees and charges that may apply. Diversification does not guarantee a profit or protect against a loss in a declining market. It is a method used to help manage investment risk. Mutual Funds and Exchange Traded Funds (ETFs) are sold by prospectus. Please consider the investment objectives, risks, charges, and expenses carefully before investing. The prospectus, which contains this and other information about the investment … is and other information about the investment company, can be obtained from the Fund Company or your financial professional. Be sure to read the prospectus carefully before deciding whether to invest. Copyright © 2026 Magnifi Communities LLC . 1166 Pearl Street, 2nd Floor, Boulder, CO 80301 Designed by WPZOOM -->
Senior Program Manager, Biotech Operations in Rancho San Diego at Fate Therapeutics Inc. | Apply now! – StudySmarter – Talents Everything for your career Find a job Senior Program Manager, Biotech Operations in Rancho San Diego Apply Now Apply Now Job Board Companies Fate Therapeutics Inc. Senior Program Manager, Biotech Operations Senior Program Manager, Biotech Operations in Rancho San Diego Rancho San Diego Full-Time 155000 - 185000 $ / year (est.) No home office possible Apply Now Apply Now F At a Glance Tasks: Lead complex biotech projects and manage cross-functional teams to drive innova … haring your experiences on platforms like ResearchGate to enhance visibility. ✨ Apply Directly On Company Websites When you find a company you're excited about, like Fate Therapeutics Inc., go directly to their careers page and apply. Many biotech firms prefer to source candidates from their own sites. Also, it shows initiative and that you’re serious about joining the team! We think you need these skills to ace Senior Program Manager, Biotech Operations in Rancho San Die … ogy Stakeholder Management Time Management Analytical Skills Some tips for your application 🫡 Showcase Your Scientific Skills: When applying for a full-time role in biotechnology, it's crucial to highlight your relevant scientific skills and experience. Include specific techniques or technologies you've worked with, like CRISPR or mass spectrometry, in your CV. This way, we can see that you have the hands-on experience necessary for the position at Fate Therapeutics … ring cross-functional team initiatives. This can make a huge difference in your application quality. How to prepare for a job interview at Fate Therapeutics Inc. ✨ Showcase Your Technical Know-How In biotechnology, it's crucial to demonstrate a strong grasp of relevant techniques and tools—so be prepared to discuss the lab methods you've used or any specific projects you’ve been part of. Bring along any data or results that highlight your contributions; we want to see … y data or results that highlight your contributions; we want to see how you can apply science to real-world problems! ✨ Brush Up on Your Problem-Solving Skills Biotech interviews often include hypothetical scenarios where you might have to troubleshoot a research problem. Practice articulating your thought process as you navigate these challenges
Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufactur … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children’s Hospital Boston and Massachusetts General Hospital May 15, 2009 | 3 min read Twitter LinkedIn Facebook Email Print LA JOLLA, Calif., May 15 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has ac … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Home - Fate Therapeutics Fate Therapeutics --> Primary Menu --> Skip to content About Us Overview Leadership Corporate Responsibility Pipeline Overview Product Candidates FT819 FT825 FT836 FT839 FT522 Early/Expanded Access Policy Science Our Cells of Interest iPSC Platform Manufacturing Publications & Presentations Patients Our Commitment Our Therapy Autoimmune Disease Cancer Clinical Trials Collaborations Careers and Culture The Fate Way Join Our Team Investors About Fate Press Releases Events & Presentations Financials & Filings SEC Filings Annual Reports and Proxies Corporate
Who is the CEO of Fate Therapeutics in 2026? Bahram Bob Valamehr's Bio | Clay THE GO-TO-MARKET CONFERENCE BY CLAY oct 8, 2026, san francisco → sculpt.clay.com Back Product Product Use Cases Use Cases Solutions Solutions Resources Resources Company Company Pricing Pricing ⌘ K Log in Get a demo Start free trial Features Claygents Research target companies and people with AI Waterfall Combine multiple data providers for the best coverage Signals and Intent Track job changes promotions or other signals Data marketplace Buy data from 150+ providers in one place . Ads Sync targeted ad audiences … pany that provides enterprise-grade solutions for data quality, governance, and application integration across cloud and hybrid environments. May 1, 2026 Read post How Much Did UpCodes Raise? Funding & Key Investors April 20, 2026 Read post Who is the CEO of Standard AI in 2026? Angie Westbrock's Bio April 15, 2026 Read post How Much Did eduMe Raise? Funding & Key Investors Read post Banner Bank Email Format Banner Bank is a regional community bank headquartered
Fate Therapeutics, Inc. (FATE) Leadership & Management Team Analysis - Simply Wall St Dashboard Portfolios Watchlist Community Discover Screener NOT FOR DISTRIBUTION Fate Therapeutics, Inc. NasdaqGM:FATE Stock Report Market Cap: US$229.6m Portfolio Add to Portfolio Holding More actions … Portfolio Add to Portfolio Holding … Company Overview 1 Valuation 2 Future Growth 3 Past Performance 4 Financial Health 5 Dividend 6 Management 7 Ownership Other Information Stock Community View Dividend Fate Therapeutics Management Management criteria checks 2/4 Fate Therapeutics' CEO is Bob Valamehr … or conditioning chemotherapy. In January 2025, the Company secured a $4 million award from the California Institute of Regenerative Medicine to support IND-enabling activities for FT836. Recent Insider Transactions Derivative • May 22 President notifies of intention to sell stock Bahram Valamehr intends to sell 29k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of May. If the sale is conducted around the recent share price of US$1.88, it would amo … nts, including Sword and Shield™ technology, support broader and more universal application without the requirements for conditioning chemotherapy. Preclinical data to be presented demonstrate potent and durable control of multiple solid and liquid xenograft tumor models of varying origin and antigen expression by FT836 activity as a monotherapy or in combination with mAbs, such as trastuzumab, cetuximab, or daratumumab (up to 100% tumor control), underscoring its broad and u … us erythematosus (SLE), including lupus nephritis (LN). The Company's RMAT application included initial clinical safety and activity data from patients treated with FT819 in its ongoing multi-center Phase 1 clinical trial. The Phase 1 study is designed to evaluate the safety and efficacy of a fludarabine (flu)-free conditioning regimen, consisting of either bendamustine alone or cyclophosphamide alone, followed by a single dose of FT819. RMAT designation includes all Bre … quirements, and potential priority review of a product's biologics license application. Announcement • Apr 09 Fate Therapeutics, Inc., Annual General Meeting, May 29, 2025 Fate Therapeutics, Inc., Annual General Meeting, May 29, 2025. Location: 12278 scripps summit drive, california, 92131, san diego, United States Announcement • Mar 06 Fate
Fate Therapeutics announces Bob Valamehr as president and CEO Skip to site menu Skip to page content Switch language: .translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Pharma Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social M
Bob Valamehr, Ph.D., M.B.A. - Fate Therapeutics Fate Therapeutics --> Primary Menu --> Skip to content About Us Overview Leadership Corporate Responsibility Pipeline Overview Product Candidates FT819 FT825 FT836 FT839 FT522 Early/Expanded Access Policy Science Our Cells of Interest iPSC Platform Manufacturing Publications & Presentations Patients Our Commitment Our Therapy Autoimmune Disease Cancer Clinical Trials Collaborations Careers and Culture The Fate Way Join Our Team Investors About Fate Press Releases Events & Presentations Financials & Filings SEC Filings Annual Report
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solut … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Soluti … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting April 16, 2026 | 4 min read Twitter Link … ndidates, including the Company’s plans to complete IND-enabling studies and to submit IND applications for its product candidates, the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the therapeutic and market potential of the Company’s research and development programs and product candidates, and the Company’s clinical and product development strategy. These and any other forward-looki … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talen
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases May 21, 2026 | 6 min read Twitter LinkedIn Facebook Email Print SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NA … n regenerative medicine, stem cell therapy, gene therapy, and clinical trials. (Grant number: CLIN2-16303) About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the man … nical investigation of its product candidates, including the Company’s plans to submit IND applications for its product candidates, the initiation and continuation of enrollment in the Company’s clinical trials, the initiation of additional clinical trials, including in new indications, and additional dose cohorts in ongoing clinical trials of the Company’s product candidates, the availability of data from the Company’s clinical trials and the Company’s plans to provide updat … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug De … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 May 5, 2026 | 8 min read Twitter LinkedIn Facebook Email Print FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot … nteractions, and the risk that the Company may not obtain adequate financing to fund its planned clinical trials and other expenses. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited t … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and G … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates February 26, 2026 | 19 min read Twitter LinkedIn Facebook Email Print Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell the … or conditioning chemotherapy. In January 2025, the Company secured a $4 million award from the California Institute of Regenerative Medicine (CIRM) to support IND-enabling activities for FT836. FT836 demonstrates clinical activity in CRC without the use of conditioning chemotherapy. In July, the FDA allowed the Company’s investigational new drug (IND) application to initiate Phase 1 clinical testing of FT836 off-the-shelf CAR T cells. The Phase 1 study is designed to assess t … g expenses and cash runway, and sufficiency of its cash and cash equivalents to fund its operations, as well as statements regarding the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, including the Company’s plans to complete IND-enabling studies and to submit IND applications for its p … payable and accrued expenses $ 22,680 $ 30,713 CIRM award liability, current portion 8,448 — Deferred revenue 381 393 Operating lease liability, current portion 4,562 7,416 Total current liabili
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Can … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates May 13, 2026 | 21 min read Twitter LinkedIn Facebook Email Print RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) … signed to Eliminate the Need for Conditioning Chemotherapy The Company plans to submit an Investigational New Drug (IND) application to the FDA to support a Phase 1 basket autoimmune study to evaluate FT839 in combination with standard of care therapies across SLE, SSc, AAV, IIM, and rheumatoid arthritis (RA), including without the use of conditioning chemotherapy, and expects to commence enrollment in the Phase 1 study in the second half of 2026. Preclinical data for FT839 w … n regenerative medicine, stem cell therapy, gene therapy, and clinical trials. (Grant number: CLIN2-16303) About FT839 FT839 is the Company’s first multi-antigen dual-CAR T-cell product candidate that is designed to express two unique CARs: a first CAR targeting the B-cell lineage marker CD19 and the second CAR targeting the immune activation marker CD38, which is often found on aberrant T, NK and B cells. FT839 is the second program to contain the Company’s Sword and Shield … or conditioning chemotherapy. In January 2025, the Company secured a $4 million award from the California Institute of Regenerative Medicine (CIRM) to support IND-enabling activities for FT836. About Fate Therapeutics’ iPSC Product Platform Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal a
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting May 11, 2026 | 12 min read Twitter LinkedIn Facebook Email Print Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity sta … reatments without Conditioning Chemotherapy for Broad and Effective Therapeutic Application in Cancer; Poster Presentation Date / Time: Wednesday, May 13, 5:00 PM - 6:30 PM ET FT836 is a next generation, off-the-shelf CAR T-cell therapy that targets the novel and inducible pan-tumor antigens MICA/B. FT836 is engineered to enable rational combination with SOC therapeutics such as mAbs, chemotherapy, radiotherapy, and immune modulators across both hematological malig … including Sword and Shield™ technology, support broader and more universal application without the requirements for conditioning chemotherapy. Preclinical data to be presented demonstrate potent and durable control of multiple solid and liquid xenograft tumor models of varying origin and antigen expression by FT836 activity as a monotherapy or in combination with mAbs, such as trastuzumab, cetuximab, or daratumumab (up to 100% tumor control), underscoring its broad … n regenerative medicine, stem cell therapy, gene therapy, and clinical trials. (Grant number: CLIN2-16303) Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the Company's product candidates, clinical studies and pr
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors May 30, 2025 | 5 min read Twitter LinkedIn Facebook Email Print SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer October 15, 2025 | 7 min read Twitter LinkedIn Facebook Email Print SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (the Company), a clinical-stage biopharmaceutical com … therapies.” In connection with his commencement of employment, the Company will grant Mr. Adawi an option to purchase 375,000 shares of the Company’s common stock with an exercise price equal to the closing price per share of the Company’s common stock as reported by NASDAQ on October 20, 2025, which will be the date of commencement of Mr. Adawi’s employment with the Company and the effective date of grant. The option is a non-qualified stock option and vests over a period of … four years, with twenty-five percent vesting on the one-year anniversary of the grant date and the remaining seventy-five percent vesting in approximately equal monthly increments over the succeeding thirty-six months, subject to Mr. Adawi’s continuous employment through each vesting date and subject to acceleration under certain circumstances as set forth in the Company’s Severance and Change in Control Policy. In addition, the Company will grant Mr. Adaw … Control Policy. In addition, the Company will grant Mr. Adawi an award of 75,000 restricted stock units, with each restricted stock unit equal to one share of the Company’s common stock. Twenty-five percent (25%) of the restricted stock units vest on November 1, 2026, and thereafter twenty-five percent (25%) of the restricted stock